Cole Beeler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cole Beeler has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Kristen Kelley
Indiana University Health, Indianapolis, IN
4 shared publicationsLana Dbeibo
Indiana University School of Medicine, Indianapolis, Ind
4 shared publicationsDouglas Webb
Infection Prevention, Indiana University Health, Indianapolis, Indiana, USA
3 shared publications- Kristen Kelley
Infection Prevention, Indiana University Health, Indianapolis, Indiana, USA
3 shared publications - Lana Dbeibo
Indiana University School of Medicine
3 shared publications Jose Azar
Indiana Clinical Translational Sciences Institute, Indiana University, Indianapolis, IN; Center for Health Innovation and Implementation Science, Indiana University School of Medicine, Indianapolis, IN; Indiana University Health, Indianapolis, IN
2 shared publications
Latest Publications
- 25 March 2024
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (8) , 878-883
Candida auris outbreak at a tertiary care hospital during the COVID-19 pandemic
- 25 March 2024
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (8) , 878-883
Candida auris outbreak at a tertiary care hospital during the COVID-19 pandemic
- 7 June 2023
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (2) , 195-199
Etiology and utility of hospital-onset bacteremia as a safety metric for targeted harm reduction
- 7 June 2023
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (2) , 195-199
Etiology and utility of hospital-onset bacteremia as a safety metric for targeted harm reduction
- 1 April 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 50 (4) , 396-399
Real world utilization of nurse-driven urinary catheter removal protocol in patients with epidural pain catheters
- 1 April 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 50 (4) , 396-399
Real world utilization of nurse-driven urinary catheter removal protocol in patients with epidural pain catheters
- Open Access
- 2 February 2021
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 43 (4) , 546-548
Assessment of a universal preprocedural screening program for coronavirus disease 2019 (COVID-19)
Objectives Study objectives were to: (1) Determine the value of a COVID-19 universal preprocedural screening program; and (2) Using the results of asymptomatic positive screens, determine the safety of resuming elective procedures. Design This was a descriptive study detailing the process and findings from implementation of a COVID-19 universal preprocedural screening program. Setting An adult academic tertiary center in Indiana. Patients Patients were included in the analysis if they were screened 96 hours prior to or within 24 hours after undergoing a procedure in the operating room, cardiac catheterization lab, or endoscopy. Methods A report was generated from the electronic health record of patients undergoing procedures from a six week period of time (May 4th-June 14th, 2020). Health records for positive screens were reviewed and classified as symptomatic if they met either criteria: (1) screen performed due to presence of COVID-19 symptoms; (2) documentation of symptoms at the time of the screen. Patients with a positive screen that did not meet symptomatic criteria were classified as asymptomatic. Descriptive statistics were used to calculate frequencies and percentages for the included sample. Results The initial sample included 2,194 patients, comprised of 46 positive and 2,148 negative screens. Out of the 46 patients who had a positive test, 17 were asymptomatic, resulting in an asymptomatic rate of 0.79% (17/2165). Conclusion Findings validated the value of the program through identification of a low rate of asymptomatic positive screens and procedural team adoption and sustainment. Findings may help inform decision making of like organizations attempting to enhance safety while resuming elective procedures.
- 2 February 2021
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 43 (4) , 546-548
Open AccessAssessment of a universal preprocedural screening program for coronavirus disease 2019 (COVID-19)
Objectives Study objectives were to: (1) Determine the value of a COVID-19 universal preprocedural screening program; and (2) Using the results of asymptomatic positive screens, determine the safety of resuming elective procedures. Design This was a descriptive study detailing the process and findings from implementation of a COVID-19 universal preprocedural screening program. Setting An adult academic tertiary center in Indiana. Patients Patients were included in the analysis if they were screened 96 hours prior to or within 24 hours after undergoing a procedure in the operating room, cardiac catheterization lab, or endoscopy. Methods A report was generated from the electronic health record of patients undergoing procedures from a six week period of time (May 4th-June 14th, 2020). Health records for positive screens were reviewed and classified as symptomatic if they met either criteria: (1) screen performed due to presence of COVID-19 symptoms; (2) documentation of symptoms at the time of the screen. Patients with a positive screen that did not meet symptomatic criteria were classified as asymptomatic. Descriptive statistics were used to calculate frequencies and percentages for the included sample. Results The initial sample included 2,194 patients, comprised of 46 positive and 2,148 negative screens. Out of the 46 patients who had a positive test, 17 were asymptomatic, resulting in an asymptomatic rate of 0.79% (17/2165). Conclusion Findings validated the value of the program through identification of a low rate of asymptomatic positive screens and procedural team adoption and sustainment. Findings may help inform decision making of like organizations attempting to enhance safety while resuming elective procedures.
- 30 September 2020
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 29 (2) , e82-e87
Outcomes of Central Nervous System Infections Treated by an Outpatient Parenteral Antimicrobial Therapy Program in a Public Teaching Hospital
Background: Outpatient parenteral antimicrobial therapy (OPAT) has been safely used to treat a variety of infections. However, limited data are available on the safety and efficacy of OPAT for central nervous system (CNS) infections. Methods: This was a retrospective, single-center study evaluating the safety and efficacy of OPAT in patients with CNS infections between July 1, 2009, and May 31, 2016. Demographic, medical, infection-specific, and drug-specific data were collected for each patient. Patients were categorized as clinical cure, probable cure, or treatment failure based on resolution or recurrence of infection for up to 1 year after OPAT completion. Safety of OPAT was evaluated through adverse drug event (ADE) and line complication (LC) monitoring. Readmission rates from OPAT-related ADE and LC were also recorded. Results: Forty-seven patients with CNS infections (mean age, 45.3 years; 70.2% male) received OPAT for a median duration of 12 days (range, 2–144 days); 1 patient was excluded from efficacy analysis because of hospice transition. Thirty-seven patients (80.4%) achieved clinical cure, 7 patients (15.2%) had probable cure, and 2 patients (4.3%) experienced treatment failure. Three patients (6.4%) experienced ADE and 4 patients (8.5%) experienced LC during OPAT. Five patients (10.6%) required rehospitalization because of worsening infection (n = 1), LC (n = 2), cerebrospinal fluid leak repair (n = 1), and insurance issues (n = 1). Six patients (12.8%) required a therapy change because of ADE or LC. Conclusions: Treating CNS infections with OPAT seems to be safe and effective based on the low failure and complication rates observed in this study.
- 30 September 2020
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 29 (2) , e82-e87
Outcomes of Central Nervous System Infections Treated by an Outpatient Parenteral Antimicrobial Therapy Program in a Public Teaching Hospital
Background: Outpatient parenteral antimicrobial therapy (OPAT) has been safely used to treat a variety of infections. However, limited data are available on the safety and efficacy of OPAT for central nervous system (CNS) infections. Methods: This was a retrospective, single-center study evaluating the safety and efficacy of OPAT in patients with CNS infections between July 1, 2009, and May 31, 2016. Demographic, medical, infection-specific, and drug-specific data were collected for each patient. Patients were categorized as clinical cure, probable cure, or treatment failure based on resolution or recurrence of infection for up to 1 year after OPAT completion. Safety of OPAT was evaluated through adverse drug event (ADE) and line complication (LC) monitoring. Readmission rates from OPAT-related ADE and LC were also recorded. Results: Forty-seven patients with CNS infections (mean age, 45.3 years; 70.2% male) received OPAT for a median duration of 12 days (range, 2–144 days); 1 patient was excluded from efficacy analysis because of hospice transition. Thirty-seven patients (80.4%) achieved clinical cure, 7 patients (15.2%) had probable cure, and 2 patients (4.3%) experienced treatment failure. Three patients (6.4%) experienced ADE and 4 patients (8.5%) experienced LC during OPAT. Five patients (10.6%) required rehospitalization because of worsening infection (n = 1), LC (n = 2), cerebrospinal fluid leak repair (n = 1), and insurance issues (n = 1). Six patients (12.8%) required a therapy change because of ADE or LC. Conclusions: Treating CNS infections with OPAT seems to be safe and effective based on the low failure and complication rates observed in this study.
- 1 December 2019
- Published by Elsevier in American Journal of Infection Control
- Vol. 47 (12) , 1505-1507
Strategies for the successful implementation of disinfecting port protectors to reduce CLABSI in a large tertiary care teaching hospital
- 1 December 2019
- Published by Elsevier in American Journal of Infection Control
- Vol. 47 (12) , 1505-1507
Strategies for the successful implementation of disinfecting port protectors to reduce CLABSI in a large tertiary care teaching hospital
- 1 January 2019
- Published by Elsevier in American Journal of Infection Control
- Vol. 47 (1) , 33-37
Using the agile implementation model to reduce central line–associated bloodstream infections
- 1 January 2019
- Published by Elsevier in American Journal of Infection Control
- Vol. 47 (1) , 33-37
Using the agile implementation model to reduce central line–associated bloodstream infections
- 1 September 2018
- Published by Elsevier in American Journal of Infection Control
- Vol. 46 (9) , 986-991
Assessing patient risk of central line-associated bacteremia via machine learning
- 1 September 2018
- Published by Elsevier in American Journal of Infection Control
- Vol. 46 (9) , 986-991
Assessing patient risk of central line-associated bacteremia via machine learning